Skip to main content

01.12.2010 | Case Report

Hunter syndrome in an 11-year old girl on enzyme replacement therapy with idursulfase: brain magnetic resonance imaging features and evolution

verfasst von: Renzo Manara, Angelica Rampazzo, Mara Cananzi, Leonardo Salviati, Rodica Mardari, Paola Drigo, Rosella Tomanin, Nicoletta Gasparotto, Elena Priante, Maurizio Scarpa

Erschienen in: Journal of Inherited Metabolic Disease | Sonderheft 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Mucopolysaccharidosis type II (MPS-II, Hunter disease) is a X-linked recessive disorder. Affected females are extremely rare, mostly due to skewed X chromosome inactivation. A few papers outline MPS-II brain magnetic resonance imaging (MRI) “gestalt” in males, but neuroradiological reports on females are still lacking. We present an 11-year-old girl affected by the severe form of MPS-II who was followed up over a time span of 8 years, focusing on clinical and brain MRI evolution. In the last 2.5 years, the patient has been treated with enzyme replacement therapy (ERT) with idursulfase (Elaprase™, Shire Human Genetic Therapies AB, Sweden). On brain and cervical MRI examination, abnormalities in our patient did not differ from those detected in male patients: J-shaped pituitary sella, enlargement of perivascular spaces, brain atrophy, mild T2-hyperintensity in the paratrigonal white matter, diffuse platyspondylia, and mild odontoid dysplasia with odontoid cup. Brain atrophy progressed despite ERT introduction, whereas perivascular space enlargement did not change significantly before and after ERT. Cognitive impairment worsened independently from the course of white matter abnormality. Despite a profound knowledge of genetic and biochemical aspects in MPS-II, neuroradiology is still poorly characterized, especially in female patients. Spinal and brain involvement and its natural course and evolution after ERT introduction still need to be clarified.
Literatur
Zurück zum Zitat Aleu FP, Terry RD, Zellweger H (1965) Electron microscopy of two cerebral biopsies in gargoylism. J Neuropathol Exp Neurol 24:304–317PubMedCrossRef Aleu FP, Terry RD, Zellweger H (1965) Electron microscopy of two cerebral biopsies in gargoylism. J Neuropathol Exp Neurol 24:304–317PubMedCrossRef
Zurück zum Zitat Broadhead DM, Kirk JM, Burt AJ et al (1986) Full expression of Hunter’s disease in a female with an X-chromosome deletion leading to non-random inactivation. Clin Genet 30:392–398PubMedCrossRef Broadhead DM, Kirk JM, Burt AJ et al (1986) Full expression of Hunter’s disease in a female with an X-chromosome deletion leading to non-random inactivation. Clin Genet 30:392–398PubMedCrossRef
Zurück zum Zitat Bunge S, Rathmann M, Steglich C et al (1998) Homologous nonallelic recombinations between the iduronate-sulfatase gene and pseudogene cause various intragenic deletions and inversions in patients with mucopolysaccharidosis type II. Eur J Hum Genet 6:492–500PubMedCrossRef Bunge S, Rathmann M, Steglich C et al (1998) Homologous nonallelic recombinations between the iduronate-sulfatase gene and pseudogene cause various intragenic deletions and inversions in patients with mucopolysaccharidosis type II. Eur J Hum Genet 6:492–500PubMedCrossRef
Zurück zum Zitat Clarke JT, Greer WL, Strasberg PM et al (1991) Hunter disease (mucopolysaccharidosis type II) associated with unbalanced inactivation of the X chromosomes in a karyotypically normal girl. Am J Hum Genet 49:289–297PubMed Clarke JT, Greer WL, Strasberg PM et al (1991) Hunter disease (mucopolysaccharidosis type II) associated with unbalanced inactivation of the X chromosomes in a karyotypically normal girl. Am J Hum Genet 49:289–297PubMed
Zurück zum Zitat Clarke JT, Willard HF, Teshima I et al (1990) Hunter disease (mucopolysaccharidosis type II) in a karyotypically normal girl. Clin Genet 37:355–362PubMedCrossRef Clarke JT, Willard HF, Teshima I et al (1990) Hunter disease (mucopolysaccharidosis type II) in a karyotypically normal girl. Clin Genet 37:355–362PubMedCrossRef
Zurück zum Zitat Clarke JT, Wilson PJ, Morris CP et al (1992) Characterization of a deletion at Xq27–q28 associated with unbalanced inactivation of the nonmutant X chromosome. Am J Hum Genet 51:316–322PubMed Clarke JT, Wilson PJ, Morris CP et al (1992) Characterization of a deletion at Xq27–q28 associated with unbalanced inactivation of the nonmutant X chromosome. Am J Hum Genet 51:316–322PubMed
Zurück zum Zitat Cudry S, Tigaud I, Froissart R et al (2000) MPS-II in females: molecular basis of two different cases. J Med Genet 272:29–37CrossRef Cudry S, Tigaud I, Froissart R et al (2000) MPS-II in females: molecular basis of two different cases. J Med Genet 272:29–37CrossRef
Zurück zum Zitat Finn CT, Vedolin L, Schwartz IV et al (2008) Magnetic resonance imaging findings in Hunter syndrome. Acta Paediatr Suppl 97:61–68PubMedCrossRef Finn CT, Vedolin L, Schwartz IV et al (2008) Magnetic resonance imaging findings in Hunter syndrome. Acta Paediatr Suppl 97:61–68PubMedCrossRef
Zurück zum Zitat Gabrielli O, Polonara G, Regnicolo L et al (2004) Correlation between cerebral MRI abnormalities and mental retardation in patients with mucopolysaccharidoses. Am J Med Genet 15:224–231CrossRef Gabrielli O, Polonara G, Regnicolo L et al (2004) Correlation between cerebral MRI abnormalities and mental retardation in patients with mucopolysaccharidoses. Am J Med Genet 15:224–231CrossRef
Zurück zum Zitat Gort L, Chabás A, Coll MJ (1999) A new polymorphism in the iduronate-2-sulphatase gene. Implications for the diagnosis of Hunter disease. J Inherit Metab Dis 22:844PubMedCrossRef Gort L, Chabás A, Coll MJ (1999) A new polymorphism in the iduronate-2-sulphatase gene. Implications for the diagnosis of Hunter disease. J Inherit Metab Dis 22:844PubMedCrossRef
Zurück zum Zitat Hers HG, van Hoof F (1969) Lysosomes and mucopolysaccharidoses. Biochem J 115:34P–36PPubMed Hers HG, van Hoof F (1969) Lysosomes and mucopolysaccharidoses. Biochem J 115:34P–36PPubMed
Zurück zum Zitat Lee C, Dineen TE, Brack M et al (1993) The mucopolysaccharidoses: characterization by cranial MR imaging. AJNR Am J Neuroradiol 14:1285–1292PubMed Lee C, Dineen TE, Brack M et al (1993) The mucopolysaccharidoses: characterization by cranial MR imaging. AJNR Am J Neuroradiol 14:1285–1292PubMed
Zurück zum Zitat Martin R, Beck M, Eng C et al (2008) Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 121:377–386CrossRef Martin R, Beck M, Eng C et al (2008) Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 121:377–386CrossRef
Zurück zum Zitat Moreira da Silva I, Froissart R, Marques dos Santos H et al (2001) Molecular basis of mucopolysaccharidosis type II in Portugal: identification of four novel mutations. Clin Genet 60:316–318PubMedCrossRef Moreira da Silva I, Froissart R, Marques dos Santos H et al (2001) Molecular basis of mucopolysaccharidosis type II in Portugal: identification of four novel mutations. Clin Genet 60:316–318PubMedCrossRef
Zurück zum Zitat Mossman J, Blunt S, Stephens R et al (1983) Hunter’s disease in a girl: association with X:5 chromosomal translocation disrupting the Hunter gene. Arch Dis Child 58:911–915PubMedCrossRef Mossman J, Blunt S, Stephens R et al (1983) Hunter’s disease in a girl: association with X:5 chromosomal translocation disrupting the Hunter gene. Arch Dis Child 58:911–915PubMedCrossRef
Zurück zum Zitat Neufeld FN, Muenzer J (2001) The mucopolysaccharidosis. In: Scriver CR, Beaudet AL, Valle D, Sly WS (eds) The metabolic and molecular basis of inherited disease. McGraw-Hill, New York, pp 3421–3452 Neufeld FN, Muenzer J (2001) The mucopolysaccharidosis. In: Scriver CR, Beaudet AL, Valle D, Sly WS (eds) The metabolic and molecular basis of inherited disease. McGraw-Hill, New York, pp 3421–3452
Zurück zum Zitat Schwartz IV, Ribeiro MG, Mota JG et al (2007) A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr Suppl 96:63–70PubMedCrossRef Schwartz IV, Ribeiro MG, Mota JG et al (2007) A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr Suppl 96:63–70PubMedCrossRef
Zurück zum Zitat Seto T, Kono K, Morimoto K et al (2001) Brain magnetic resonance imaging in 23 patients with mucopolysaccharidoses and the effect of bone marrow transplantation. Ann Neurol 50:79–92PubMedCrossRef Seto T, Kono K, Morimoto K et al (2001) Brain magnetic resonance imaging in 23 patients with mucopolysaccharidoses and the effect of bone marrow transplantation. Ann Neurol 50:79–92PubMedCrossRef
Zurück zum Zitat Shinomiya N, Nagayama T, Fujioka Y et al (1996) MRI in the mild type of mucopolysaccharidosis II (Hunter’s syndrome). Neuroradiology 38:483–485PubMedCrossRef Shinomiya N, Nagayama T, Fujioka Y et al (1996) MRI in the mild type of mucopolysaccharidosis II (Hunter’s syndrome). Neuroradiology 38:483–485PubMedCrossRef
Zurück zum Zitat Sleddens HF, Oostra BA, Brinkmann AO et al (1993) Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. Hum Mol Genet 2:493PubMedCrossRef Sleddens HF, Oostra BA, Brinkmann AO et al (1993) Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. Hum Mol Genet 2:493PubMedCrossRef
Zurück zum Zitat Sukegawa K, Song XQ, Masuno M et al (1997) Hunter disease in a girl caused by R468Q mutation in the iduronate-2-sulfatase gene and skewed inactivation of the X chromosome carrying the normal allele. Hum Mut 10:361–367PubMedCrossRef Sukegawa K, Song XQ, Masuno M et al (1997) Hunter disease in a girl caused by R468Q mutation in the iduronate-2-sulfatase gene and skewed inactivation of the X chromosome carrying the normal allele. Hum Mut 10:361–367PubMedCrossRef
Zurück zum Zitat Sukegawa K, Matsuzaki T, Fukuda S et al (1998) Brother/sister siblings affected with Hunter disease: evidence for skewed X chromosome inactivation. Clin Genet 53:96–101PubMedCrossRef Sukegawa K, Matsuzaki T, Fukuda S et al (1998) Brother/sister siblings affected with Hunter disease: evidence for skewed X chromosome inactivation. Clin Genet 53:96–101PubMedCrossRef
Zurück zum Zitat Timms KM, Bondeson ML, Ansari-Lari MA et al (1997) Molecular and phenotypic variation in patients with severe Hunter syndrome. Hum Mol Genet 6:479–486PubMedCrossRef Timms KM, Bondeson ML, Ansari-Lari MA et al (1997) Molecular and phenotypic variation in patients with severe Hunter syndrome. Hum Mol Genet 6:479–486PubMedCrossRef
Zurück zum Zitat Tuschl K, Gal A, Paschke E et al (2005) Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr Neurol 32:270–272PubMedCrossRef Tuschl K, Gal A, Paschke E et al (2005) Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr Neurol 32:270–272PubMedCrossRef
Zurück zum Zitat Vallance HD, Bernard L, Rashed M et al (1999) Identification of 6 new mutations in the iduronate sulfatase gene. Hum Mutat 13:338PubMedCrossRef Vallance HD, Bernard L, Rashed M et al (1999) Identification of 6 new mutations in the iduronate sulfatase gene. Hum Mutat 13:338PubMedCrossRef
Zurück zum Zitat Vedolin L, Schwartz IV, Komlos M et al (2007a) Brain MRI in mucopolysaccharidosis: effect of aging and correlation with biochemical findings. Neurology 69:917–924PubMedCrossRef Vedolin L, Schwartz IV, Komlos M et al (2007a) Brain MRI in mucopolysaccharidosis: effect of aging and correlation with biochemical findings. Neurology 69:917–924PubMedCrossRef
Zurück zum Zitat Vedolin L, Schwartz IV, Komlos M et al (2007b) Correlation of MR imaging and MR spectroscopy findings with cognitive impairment in mucopolysaccharidosis II. Am J Neuroradiol 28:1029–1033PubMedCrossRef Vedolin L, Schwartz IV, Komlos M et al (2007b) Correlation of MR imaging and MR spectroscopy findings with cognitive impairment in mucopolysaccharidosis II. Am J Neuroradiol 28:1029–1033PubMedCrossRef
Zurück zum Zitat Winchester B, Young E, Geddes S et al (1992) Female twin with Hunter disease due to non random inactivation of the X-chromosome: a consequence of twinning. Am J Med Genet 44:834–838PubMedCrossRef Winchester B, Young E, Geddes S et al (1992) Female twin with Hunter disease due to non random inactivation of the X-chromosome: a consequence of twinning. Am J Med Genet 44:834–838PubMedCrossRef
Zurück zum Zitat Young ID, Harper PS, Newcombe RG et al (1982) A clinical and genetic study of Hunter’s syndrome 2: differences between the mild and severe forms. J Med Genet 19:408–411PubMedCrossRef Young ID, Harper PS, Newcombe RG et al (1982) A clinical and genetic study of Hunter’s syndrome 2: differences between the mild and severe forms. J Med Genet 19:408–411PubMedCrossRef
Metadaten
Titel
Hunter syndrome in an 11-year old girl on enzyme replacement therapy with idursulfase: brain magnetic resonance imaging features and evolution
verfasst von
Renzo Manara
Angelica Rampazzo
Mara Cananzi
Leonardo Salviati
Rodica Mardari
Paola Drigo
Rosella Tomanin
Nicoletta Gasparotto
Elena Priante
Maurizio Scarpa
Publikationsdatum
01.12.2010
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe Sonderheft 3/2010
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-009-9023-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.